Results 51 to 60 of about 39,266 (270)

Pharmacokinetic‐pharmacodynamic modelling of risankizumab using chronic plaque psoriasis real‐world data

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Risankizumab is a high‐cost biologic treatment for chronic plaque psoriasis, an immune‐mediated inflammatory disease presenting with painful red scaly skin lesions. Inter‐individual heterogeneity in treatment response may be better addressed with personalised rather than fixed dosing. We sought to develop a pharmacokinetic/pharmacodynamic (
Charlotte M. Thomas, Jessica Ruoheng Wei, David Baudry, Zehra Arkir, Bola Coker, Tejus Dasandi, Kingsley Powell, Monica Arenas‐Hernandez, Jenny Leung, Krystal Rawstron, Chioma Nwaogu, Richard Woolf, Andrew E. Pink, Jonathan Barker, Joseph F. Standing, Catherine H. Smith, Satveer K. Mahil   +16 more
wiley   +1 more source

Health-related quality of life in patients with generalized pustular psoriasis – a Swedish register study

Annals of Medicine
Background Real-world data on health-related quality of life (HRQoL) in generalized pustular psoriasis (GPP) are scarce and studies have been restricted in terms of instruments used for assessments.Objective To assess generic and dermatology-specific ...
Jenny M. Norlin, Sofia Löfvendahl, Marcus Schmitt-Egenolf   +2 more
doaj   +1 more source

Biologics in Plaque Psoriasis

Canadian Journal of Health Technologies, 2021
Health Canada has approved 11 biologics for the treatment of adults with moderate-to-severe plaque psoriasis (PsO). These biologics can be divided into 2 groups based on mechanisms of action and market authorization dates: Old-generation biologics (5): include anti–tumour necrosis factor (TNF) agents (etanercept, adalimumab ...
Peter Dyrda, Sirjana Pant
openaire   +2 more sources

Intraosseous sarcoidosis imitating peri‐implantitis: A case study

Clinical Advances in Periodontics, EarlyView.
Abstract Background Sarcoidosis is a multisystem granulomatous disorder of unknown cause, typically affecting the lungs and lymph nodes, but it can also involve the eyes, skin, heart, bones, and other organs. The exact cause is unclear, but genetic factors and environmental triggers like infections, chemicals, or dust may play a role.
Magdalena Orlowska, David S. Gottlieb, Kenneth S. Kornman   +2 more
wiley   +1 more source

Palmoplantar plaque psoriasis responsive to upadacitinib: A report of two cases

SAGE Open Medical Case Reports
Palmoplantar plaque psoriasis is more resistant to therapy compared to other phenotypes of psoriasis. To our knowledge, there are no reports of the efficacy of Janus kinase (JAK) inhibitors for palmoplantar plaque psoriasis.
Bohmyi Choi, Heidi Oi-Yee Li, Steven J Glassman   +2 more
doaj   +1 more source

Efficacy of ω-3 supplementation in patients with psoriasis:a meta-analysis of randomized controlled trials [PDF]

, 2019
Several studies have been conducted with the aim of investigating the effect of Omega(Ï )-3 on different psoriasis indices including Psoriasis Area and Severity Index (PASI) score, erythema, scaling, itching, area involved, and infiltration. Nevertheless,
Clark, Cain, Jafarnejad, Sadegh, Nahavandi, Mina, Taghizadeh, Mohsen   +3 more
core   +2 more sources

Voclosporin‐induced gingival enlargement: A case report

Clinical Advances in Periodontics, EarlyView.
Abstract Background Drug‐influenced gingival enlargement (DIGE) is a recognized adverse effect of certain medications, particularly immunosuppressants like cyclosporin and tacrolimus. However, there have been no documented cases of DIGE associated with voclosporin, a newer calcineurin inhibitor used primarily to treat lupus nephritis.
Francesca Racca, Jessica M. Greco, Dimitris N. Tatakis   +2 more
wiley   +1 more source

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3) [PDF]

, 2018
Background: The study aimed to assess 52-week efficacy and safety of secukinumab self-administration by autoinjector in patients with active psoriatic arthritis (PsA) in the FUTURE 3 study (ClinicalTrials.gov NCT01989468).
Andersson, Mats, Blanco, Ricardo, Dokoupilova, Eva, FUTURE 3 study group, Kajekar, Radhika, McInnes, Iain B, Mease, Philip J, Mpofu, Shephard, Nash, Peter, Pricop, Luminita, Rahman, Proton, Ritchlin, Christopher T   +11 more
core   +1 more source

Advancing Maternal Health with Long‐Acting Therapeutics: Priorities, Efficacy and Safety Considerations, and Emerging Technologies

Clinical Pharmacology &Therapeutics, EarlyView.
Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott, Sharon Nachman, Ethel D. Weld, Rachel Daley, Shakir Atoyebi, Robert Bies, Catriona Waitt, Adeniyi Olagunju   +7 more
wiley   +1 more source

Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis. [PDF]

, 2020
Risankizumab-rzaa (Skyrizi®; AbbVie) is a humanized IgG monoclonal antibody directed against interleukin-23p19 (IL-23p19) indicated for the treatment of moderate-to-severe psoriasis in adults who are candidates for systemic therapy or phototherapy.
Liao, Wilson, Myers, Bridget, Reddy, Vidhatha, Yang, Eric J   +3 more
core   +1 more source